Halozyme Therapeutics (HALO) Earnings Analysis

Halozyme Therapeutics (HALO) has no confirmed upcoming earnings date. Last quarter (2026-05-11) it beat with EPS 1.6 USD vs 1.55 USD est (+3.2%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E 26.65.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does HALO next report earnings?

No confirmed upcoming earnings date is currently scheduled for HALO. This page updates as the calendar is published.

HALO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-111.6 USD1.55 USD+3.2%Beat
2026-02-17-0.24 USD2.15 USD-111.2%Miss
2025-11-031.72 USD1.63 USD+5.5%Beat
2025-02-181.26 USD1.17 USD+7.7%Beat
2024-10-311.27 USD0.98 USD+29.6%Beat

Beat rate: 4/5 (80%) over reported quarters with consensus data.

HALO valuation and analyst view

Trailing P/E26.65
Trailing EPS2.953 USD
Price / book41.86
Dividend yield0.00%
Market cap9.32B
Analyst consensusBuy (17 buy / 9 hold / 1 sell)
Avg price target92.67 USD

Related research pages

Frequently asked questions

When is Halozyme Therapeutics (HALO)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for HALO. This page updates as the calendar is published.

Did HALO beat earnings last quarter?

In its 2026-05-11 report, HALO posted EPS of 1.6 USD versus a 1.55 USD estimate — a beat of 3.2%.

What is HALO's earnings track record?

Over the last 5 reported quarters with consensus data, HALO beat estimates 4 times (80%).

What is HALO's current P/E ratio and EPS?

HALO trades at a trailing P/E of 26.65 on trailing EPS of 2.95269332340195 USD.

What do analysts rate HALO?

Analyst consensus is "Buy" across 27 ratings (0 strong buy, 17 buy, 9 hold, 1 sell, 0 strong sell). Average 12-month price target: 92.67 USD.